Treatment Satisfaction Among Patients Using Anti-Inflammatory Topical Medications for Dry Eye Disease

Darrell E White,1 Yang Zhao,2 Hemalatha Jayapalan,3 Pattabhi Machiraju,3 Ramu Periyasamy,3 Abayomi Ogundele2 1SkyVision Centers, Westlake, OH, USA; 2Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA; 3Indegene, Inc., Bangalore, IndiaCorrespondence: Abayomi OgundeleMedical Affairs, Sun Pharmace...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	White DE, Zhao Y, Jayapalan H, Machiraju P, Periyasamy R, Ogundele A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	patient satisfaction dry eye disease cyclosporine lifitegrast ocular surface Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/d1f041688a034b06a351b097cf4f1cd9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d1f041688a034b06a351b097cf4f1cd9
record_format	dspace
spelling	oai:doaj.org-article:d1f041688a034b06a351b097cf4f1cd92021-12-02T11:04:37ZTreatment Satisfaction Among Patients Using Anti-Inflammatory Topical Medications for Dry Eye Disease1177-5483https://doaj.org/article/d1f041688a034b06a351b097cf4f1cd92020-03-01T00:00:00Zhttps://www.dovepress.com/treatment-satisfaction-among-patients-using-anti-inflammatory-topical--peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Darrell E White,1 Yang Zhao,2 Hemalatha Jayapalan,3 Pattabhi Machiraju,3 Ramu Periyasamy,3 Abayomi Ogundele2 1SkyVision Centers, Westlake, OH, USA; 2Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA; 3Indegene, Inc., Bangalore, IndiaCorrespondence: Abayomi OgundeleMedical Affairs, Sun Pharmaceutical Industries, Inc., 2 Independence Way, Princeton, NJ 08540, USAEmail abayomi.ogundele@sunpharma.comPurpose: To assess patient satisfaction among current and former users of the anti-inflammatory topical medications, cyclosporine A 0.05% (CYC) and lifitegrast 5.0% (LIF), for the management of dry eye disease (DED).Patients and Methods: Patients with DED were recruited via physician referral to participate in a survey. Current users of CYC or LIF were asked to rate their experience in terms of satisfaction, side effects, and limitation of activities. Switchers of CYC to LIF or LIF to CYC were asked to rate the importance of potential reasons for switching.Results: Surveys were completed by 207 patients currently treated with CYC (n=98), LIF (n=96), or other DED medications (n=13). Although overall satisfaction with current treatment was high, current users of CYC and LIF reported ineffective relief of DED symptoms (31% and 22%, respectively) and dissatisfaction with the time to onset of effect (29% and 11%). Substantial proportions of patients reported ‘sometimes’, “usually”, or ‘always’ experiencing the following side effects: burning sensation (72% CYC, 64% LIF), itching (43% CYC, 44% LIF), altered sensation of taste (21% CYC, 56% LIF), blurred vision (37% CYC, 50% LIF), and discharge (28% CYC, 30% LIF). Of the 30 switchers of CYC to LIF and 31 switchers of LIF to CYC, the majority reported inability to relieve DED symptoms as a very or extremely important switching reason. Despite switching, one in four patients were somewhat dissatisfied or dissatisfied with their current medication, with 37% of patients reporting ineffective symptom relief.Conclusion: Although the rate of overall satisfaction was generally high with both LIF and CYC, many patients were unable to achieve effective symptom relief and commonly experienced side effects. The proportion of patients who were dissatisfied and/or unable to achieve effective symptom relief even after switching suggests the need for additional treatment options for managing DED.Keywords: patient satisfaction, dry eye disease, cyclosporine, lifitegrast, ocular surfaceWhite DEZhao YJayapalan HMachiraju PPeriyasamy ROgundele ADove Medical Pressarticlepatient satisfactiondry eye diseasecyclosporinelifitegrastocular surfaceOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 14, Pp 875-883 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	patient satisfaction dry eye disease cyclosporine lifitegrast ocular surface Ophthalmology RE1-994
spellingShingle	patient satisfaction dry eye disease cyclosporine lifitegrast ocular surface Ophthalmology RE1-994 White DE Zhao Y Jayapalan H Machiraju P Periyasamy R Ogundele A Treatment Satisfaction Among Patients Using Anti-Inflammatory Topical Medications for Dry Eye Disease
description	Darrell E White,1 Yang Zhao,2 Hemalatha Jayapalan,3 Pattabhi Machiraju,3 Ramu Periyasamy,3 Abayomi Ogundele2 1SkyVision Centers, Westlake, OH, USA; 2Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA; 3Indegene, Inc., Bangalore, IndiaCorrespondence: Abayomi OgundeleMedical Affairs, Sun Pharmaceutical Industries, Inc., 2 Independence Way, Princeton, NJ 08540, USAEmail abayomi.ogundele@sunpharma.comPurpose: To assess patient satisfaction among current and former users of the anti-inflammatory topical medications, cyclosporine A 0.05% (CYC) and lifitegrast 5.0% (LIF), for the management of dry eye disease (DED).Patients and Methods: Patients with DED were recruited via physician referral to participate in a survey. Current users of CYC or LIF were asked to rate their experience in terms of satisfaction, side effects, and limitation of activities. Switchers of CYC to LIF or LIF to CYC were asked to rate the importance of potential reasons for switching.Results: Surveys were completed by 207 patients currently treated with CYC (n=98), LIF (n=96), or other DED medications (n=13). Although overall satisfaction with current treatment was high, current users of CYC and LIF reported ineffective relief of DED symptoms (31% and 22%, respectively) and dissatisfaction with the time to onset of effect (29% and 11%). Substantial proportions of patients reported ‘sometimes’, “usually”, or ‘always’ experiencing the following side effects: burning sensation (72% CYC, 64% LIF), itching (43% CYC, 44% LIF), altered sensation of taste (21% CYC, 56% LIF), blurred vision (37% CYC, 50% LIF), and discharge (28% CYC, 30% LIF). Of the 30 switchers of CYC to LIF and 31 switchers of LIF to CYC, the majority reported inability to relieve DED symptoms as a very or extremely important switching reason. Despite switching, one in four patients were somewhat dissatisfied or dissatisfied with their current medication, with 37% of patients reporting ineffective symptom relief.Conclusion: Although the rate of overall satisfaction was generally high with both LIF and CYC, many patients were unable to achieve effective symptom relief and commonly experienced side effects. The proportion of patients who were dissatisfied and/or unable to achieve effective symptom relief even after switching suggests the need for additional treatment options for managing DED.Keywords: patient satisfaction, dry eye disease, cyclosporine, lifitegrast, ocular surface
format	article
author	White DE Zhao Y Jayapalan H Machiraju P Periyasamy R Ogundele A
author_facet	White DE Zhao Y Jayapalan H Machiraju P Periyasamy R Ogundele A
author_sort	White DE
title	Treatment Satisfaction Among Patients Using Anti-Inflammatory Topical Medications for Dry Eye Disease
title_short	Treatment Satisfaction Among Patients Using Anti-Inflammatory Topical Medications for Dry Eye Disease
title_full	Treatment Satisfaction Among Patients Using Anti-Inflammatory Topical Medications for Dry Eye Disease
title_fullStr	Treatment Satisfaction Among Patients Using Anti-Inflammatory Topical Medications for Dry Eye Disease
title_full_unstemmed	Treatment Satisfaction Among Patients Using Anti-Inflammatory Topical Medications for Dry Eye Disease
title_sort	treatment satisfaction among patients using anti-inflammatory topical medications for dry eye disease
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/d1f041688a034b06a351b097cf4f1cd9
work_keys_str_mv	AT whitede treatmentsatisfactionamongpatientsusingantiinflammatorytopicalmedicationsfordryeyedisease AT zhaoy treatmentsatisfactionamongpatientsusingantiinflammatorytopicalmedicationsfordryeyedisease AT jayapalanh treatmentsatisfactionamongpatientsusingantiinflammatorytopicalmedicationsfordryeyedisease AT machirajup treatmentsatisfactionamongpatientsusingantiinflammatorytopicalmedicationsfordryeyedisease AT periyasamyr treatmentsatisfactionamongpatientsusingantiinflammatorytopicalmedicationsfordryeyedisease AT ogundelea treatmentsatisfactionamongpatientsusingantiinflammatorytopicalmedicationsfordryeyedisease
_version_	1718396318267736064

Treatment Satisfaction Among Patients Using Anti-Inflammatory Topical Medications for Dry Eye Disease

Ejemplares similares